Organovo Inc. (ONVO)
0.60
-0.10 (-14.30%)
At close: Mar 04, 2025, 3:59 PM
0.57
-5.05%
After-hours: Mar 04, 2025, 04:34 PM EST
No 1D chart data available
| Bid | 0.57 |
| Market Cap | 10.48M |
| Revenue (ttm) | 117.93K |
| Net Income (ttm) | -11.97M |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | -0.71 |
| Forward PE | -0.47 |
| Analyst | n/a |
| Ask | 0.59 |
| Volume | 1,319,886 |
| Avg. Volume (20D) | 7,914,144 |
| Open | 0.68 |
| Previous Close | 0.70 |
| Day's Range | 0.58 - 0.72 |
| 52-Week Range | 0.32 - 1.83 |
| Beta | 0.45 |
About ONVO
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive h...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 14, 2012
Employees 14
Stock Exchange NASDAQ
Ticker Symbol ONVO
Website https://www.organovo.com
Next Earnings Release
Organovo Inc. is scheduled to release its earnings on May 30, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+244.17%
Organovo shares are trading higher after the compa...
Unlock content with
Pro Subscription
3 months ago
-0.39%
Organovo Holdings shares are trading higher after the company announced it will present clinical data of FXR314 in its Phase 2 MASH study in an oral presentation sponsored by the American Association for the Study of Liver Diseases.
